Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer : results from the prospective randomised, open-label phase 3 Scandinavian Prostate Cancer Group 12 trial

Göran Ahlgren; Per Flodgren; Teuvo Tammela; Pirkko Kellokumpu-Lehtinen; Michael Borre; Anders Angelsen; Jon Iversen; Asgerdur Sverrisdottir; Eirikur Jonsson; Lisa Sengelov

doi:10.1016/j.eururo.2018.01.012

Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer : results from the prospective randomised, open-label phase 3 Scandinavian Prostate Cancer Group 12 trial

Göran Ahlgren
, Per Flodgren
, Teuvo Tammela
, Pirkko Kellokumpu-Lehtinen
, Michael Borre
, Anders Angelsen
, Jon Iversen
, Asgerdur Sverrisdottir
, Eirikur Jonsson
, Lisa Sengelov

Research output: Contribution to journal › Article › Scientific › peer-review

56 Citations (Scopus)

Original language	English
Pages (from-to)	870-876
Journal	European Urology
Volume	73
Issue number	6
DOIs	https://doi.org/10.1016/j.eururo.2018.01.012
Publication status	Published - 2018
Publication type	A1 Journal article-refereed

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

adjuvant
docetaxel
prostate cancer
radical prostatectomy
randomised trial

Publication forum classification

Publication forum level 3

Access to Document

10.1016/j.eururo.2018.01.012

Cite this

Ahlgren, G., Flodgren, P., Tammela, T., Kellokumpu-Lehtinen, P., Borre, M., Angelsen, A., Iversen, J., Sverrisdottir, A., Jonsson, E., & Sengelov, L. (2018). Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer : results from the prospective randomised, open-label phase 3 Scandinavian Prostate Cancer Group 12 trial. European Urology, 73(6), 870-876. https://doi.org/10.1016/j.eururo.2018.01.012

@article{4b80446d5fe34eea9ef92bf05019d312,

title = "Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer : results from the prospective randomised, open-label phase 3 Scandinavian Prostate Cancer Group 12 trial",

keywords = "adjuvant, docetaxel, prostate cancer, radical prostatectomy, randomised trial, adjuvant, docetaxel, prostate cancer, radical prostatectomy, randomised trial",

author = "G{\"o}ran Ahlgren and Per Flodgren and Teuvo Tammela and Pirkko Kellokumpu-Lehtinen and Michael Borre and Anders Angelsen and Jon Iversen and Asgerdur Sverrisdottir and Eirikur Jonsson and Lisa Sengelov",

year = "2018",

doi = "10.1016/j.eururo.2018.01.012",

language = "English",

volume = "73",

pages = "870--876",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "6",

}

Ahlgren, G, Flodgren, P, Tammela, T , Kellokumpu-Lehtinen, P, Borre, M, Angelsen, A, Iversen, J, Sverrisdottir, A, Jonsson, E & Sengelov, L 2018, 'Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer : results from the prospective randomised, open-label phase 3 Scandinavian Prostate Cancer Group 12 trial', European Urology, vol. 73, no. 6, pp. 870-876. https://doi.org/10.1016/j.eururo.2018.01.012

Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer : results from the prospective randomised, open-label phase 3 Scandinavian Prostate Cancer Group 12 trial. / Ahlgren, Göran; Flodgren, Per; Tammela, Teuvo et al.
In: European Urology, Vol. 73, No. 6, 2018, p. 870-876.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer : results from the prospective randomised, open-label phase 3 Scandinavian Prostate Cancer Group 12 trial

AU - Ahlgren, Göran

AU - Flodgren, Per

AU - Tammela, Teuvo

AU - Kellokumpu-Lehtinen, Pirkko

AU - Borre, Michael

AU - Angelsen, Anders

AU - Iversen, Jon

AU - Sverrisdottir, Asgerdur

AU - Jonsson, Eirikur

AU - Sengelov, Lisa

PY - 2018

Y1 - 2018

KW - adjuvant

KW - docetaxel

KW - prostate cancer

KW - radical prostatectomy

KW - randomised trial

KW - adjuvant

KW - docetaxel

KW - prostate cancer

KW - radical prostatectomy

KW - randomised trial

U2 - 10.1016/j.eururo.2018.01.012

DO - 10.1016/j.eururo.2018.01.012

M3 - Article

SN - 0302-2838

VL - 73

SP - 870

EP - 876

JO - European Urology

JF - European Urology

IS - 6

ER -